Treatment of idiopathic nephrotic syndrome with levamisole

Area of Science:

• Pediatric Nephrology
• Immunology
• Pharmacology

Background:

• Idiopathic nephrotic syndrome (INS) is a significant kidney disorder in children.
• Frequently relapsing INS often requires long-term immunosuppressive therapy, including corticosteroids.
• Corticosteroid therapy is associated with numerous adverse effects.

Purpose of the Study:

• To evaluate the efficacy and safety of levamisole in children with frequently relapsing idiopathic nephrotic syndrome.
• To determine if levamisole can reduce the need for corticosteroid therapy in this patient population.

Main Methods:

• A prospective study involving 30 children with frequently relapsing INS.
• Treatment with levamisole at a dose of 2.5 mg/kg body weight twice weekly for a mean duration of 9.9 months.
• Monitoring for relapses, corticosteroid dosage adjustments, and adverse events, including neutrophil counts.

Main Results:

• Levamisole was effective in 16 out of 30 children, enabling significant corticosteroid reduction without relapses.
• The drug was ineffective in 14 patients.
• Patients who responded to levamisole were older at INS onset (mean 5.8 years vs. 2.8 years).
• Neutrophil counts decreased in 7 responders, with transient granulocytopenia observed in 3 patients.

Conclusions:

• Levamisole may be an effective treatment option for children with frequently relapsing idiopathic nephrotic syndrome.
• The use of levamisole in this context appears to be associated with minimal side effects.
• Further research is warranted to confirm these findings and elucidate the mechanism of action.